Biomaterial Database

Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. 1981

M H Branchey, and L B Branchey, and M A Richardson

The authors decreased neuroleptic medication in 21 chronic schizophrenic patients in an attempt to minimize the risks of tardive dyskinesia. Level of psychopathology and severity of dyskinetic symptoms were monitored while the neuroleptic was gradually decreased over 3 months and then discontinued. Only 1 patient relapsed during drug decrease; however, 15 patients relapsed within 6 months after drug withdrawal. After relapse, medication was gradually increased. The doses needed to induce recovery were higher than those which had been sufficient to prevent relapse during gradual drug reduction. Dyskinetic symptoms were not significantly modified during drug reduction but increased significantly after drug discontinuation.

UI	MeSH Term	Description	Entries
D008152	Loxapine	An antipsychotic agent used in SCHIZOPHRENIA.	Loxapinsuccinate,Oxilapine,2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine,CL-71,563,Cloxazepine,Loxapine Hydrochloride,Loxapine Monohydrochloride,Loxapine Succinate,Loxipine Maleate,Loxipine Succinate,Loxitane,CL 71,563,CL71,563,Hydrochloride, Loxapine,Maleate, Loxipine,Succinate, Loxapine
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D012008	Recurrence	The return of a sign, symptom, or disease after a remission.	Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002908	Chronic Disease	Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D003989	Dibenzoxazepines
D004311	Double-Blind Method	A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.	Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004409	Dyskinesia, Drug-Induced	Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)	Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260	Female		Females